Abstract Background Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma (RCC). The OMNIVORE trial (NCT03652142) investigated a response-adaptive strategy including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition...
M. Serzan, Wan-Ling Xie, B. McGregor et al.· The Oncologist· 0 citations
A scRNA-seq atlas of tumors from metastatic RCC found a novel factor, Hsp70, that in lymphocytes strongly predicts response and greatly extended PFS after ICI, indicating that Hsp70 expression in lymphocytes predicts response to ICI across timepoints and cohorts.
Ethan C. Burns, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.
Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al.· The Oncologist· 0 citations
A tissue residency gene program in Tex cells associated with non-response to immunotherapy was identified and nominates resident memory exhausted CD8+ T cells as a targetable subset of cells to improve CD8+ T cell-mediated anti-tumor immunity.
Rishabh Rout, S. Kashima, M. Hugaboom et al.· The Oncologist· 0 citations
It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.
Zhao-Chen Ye, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
